Skip to content

RNAC - Cartesian Therapeutics, Inc. - AlphaYou

Discover Compare Pricing

Sign in Sign up

Home Smart money Buy calls Analyze

Back to stock searchR

Cartesian Therapeutics Inc.

RNAC · NASDAQ

Save to watchlist

Price is syncing

Reported smart-money activity for this stock is still below.

R

RNACCartesian Therapeutics Inc.

Overview

No source-backed view yet. This page is available for price, fundamentals, and future receipts as coverage warms.

Key stats

Aug 21

52-wk high: $11.80
52-wk low: $5.60
Prev close: $8.95
Mkt cap: $317.4M
Fwd P/E: 25.1x
Beta: 0.56

Smart money

8 funds hold a position.

Real smart money

Funds holding this stock

8 holders

Combined position$50.9M

SQ
Squarepoint
Q2 2026 13F
$23.5M
position
AQ
AQR
Q2 2026 13F

Earnings

Reported Aug 6, 2026

Earnings came in $1.29 a share above what analysts expected.

Documents

Quarterly report10-Q Annual report10-K

Financials

Fundamentals

Is the business strong?

This company is running thin margins.

Net margin: 0.0%
Forward P/E: 25.06
Market cap: $317M

Valuation

P/S214.88
P/B31.26

Quality

Operating margin-6680.0%

Technicals

Technicals

Price structure

No data yet

Technicals sync when verified market data is available. No sample data is shown.

Company

Symbol: RNAC
Exchange: NASDAQ
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Market cap: $317.38M
Beta: 0.56

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

See the 12-month consensus target and the buy/hold/sell rating split.

Unlock the full results

Research hubs
About
Editorial policy
Methodology
Source coverage
Corrections

Privacy
Terms
Refunds
Disclaimer

© 2026 AlphaYou. All rights reserved.Not financial advice. Do your own research. Informational data only; past performance does not predict future results.

P/S

214.9x

P/B

31.3x

Profit margin

+0.0%

Op margin

-6680.0%

ROE

-7029.0%

$3.7M

position

MI

Millennium

Israel Englander · Q2 2026 13F

$3.2M

position

5 more holders

Lite opens all of them for $16.50/month, paid yearly.

Unlock all 5 holders

Coverage gaps for RNAC

No recent insider trade
No recent Congress trade
No recent market-voice mention

Earnings per share

$0.46+$1.29

-$0.83 expected

Next report

What the street expects next

ROE

-7029.0%

ROA-17.4%

Growth

Beta0.56